Product menu

Resources for your patients

SHINGRIX Patient Brochure

SHINGRIX Patient Brochure

View
Shingles Risk Quiz

Shingles Risk Quiz

View
SHINGRIX Dose Reminder Tear Pad

SHINGRIX Dose Reminder Tear Pad

View
Patient Brochure Punjabi

Patient Brochure Punjabi

View
Patient Brochure Chinese

Patient Brochure Chinese

View
Graph icon

Efficacy data for SHINGRIX1

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.1

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
Virus icon

Did you know age is the dominant driver of shingles?

Learn about age-related decline in immunity.3

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  3. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24